NRSN
NeuroSense Therapeutics (NRSN)
$79
About NeuroSense Therapeutics (NRSN)
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
Details
Daily high
$0.90
Daily low
$0.77
Price at open
--
52 Week High
$2.52
52 Week Low
$0.63
Market cap
28.4M
Dividend yield
0.00%
Volume
100
Avg. volume
153,666
P/E ratio
-1.38
NeuroSense Therapeutics News
Details
Daily high
$0.90
Daily low
$0.77
Price at open
--
52 Week High
$2.52
52 Week Low
$0.63
Market cap
28.4M
Dividend yield
0.00%
Volume
100
Avg. volume
153,666
P/E ratio
-1.38